Author: John Pinching

NICE recommends non‑hormonal therapy for moderate to severe vasomotor symptoms

BE BOLD trial shows bimekizumab outperforms risankizumab at Week 16

Early data show favourable safety and sustained target engagement for oral EP4 receptor antagonist

Study will assess whether microbiome therapy can protect gut diversity during transplantation

Phase 3 Mascot study reaches key milestone for potential first-in-class therapy